News >

Trabectedin Offers Third-Line Option in Uterine Leiomyosarcoma

Greg Kennelty
Published: Thursday, Mar 24, 2016

Trabectedin was approved as of October 2015, so it is commercially available for doctors to use. In general, uterine leiomyosarcoma and sarcomas are relatively rare diseases. Not everyone has a lot of experience taking care of those patients or experience using drugs that have this relatively narrow indication.

It is useful to get the information out there when new drugs become available, and then helpful to show people how to use them—and use them safely.

What do you hope community oncologists will take away from this study?

I hope they will see that progress is being made in uterine leiomyosarcomas. When I started working in this field, there were very few studies and few drugs for uterine leiomyosarcomas. We have made a lot of progress.

I hope they see that clinical research does drive the field forward in rare tumors and, specifically, in uterine leiomyosarcomas. When facing a patient with uterine leiomyosarcoma, know that there is a list of agents to think about as treatments. Have some idea on how to sequence those treatments. Finally, know that there are experts to go to for advice about to best take care of these women.


  1. Hensley ML, Patel SR, Mehren MV, et al. Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: a subgroup analysis of the randomized phase 3 SAR-3007 study. Presented at: 2016 SGO Annual Meeting. March 19-22, 2016. San Diego, CA. Abstract 3.
  2. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase iii randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786-793.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication